Bristol Gets CHMP Positive Opinion for Opdivo Flat Dosing in Melanoma

Bristol-Myers Squibb Co. (BMY) on Tuesday said the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of a flat-dosing schedule for its cancer drug Opdivo in adults with the skin cancer melanoma.

The New York biopharmaceutical company said the committee’s positive opinion covers two-week and four-week flat dosing of Opdivo for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

The European Commission, which generally follows the CHMP’s recommendations, will review the decision for final action, Bristol-Myers said.

https://www.marketscreener.com/BRISTOL-MYERS-SQUIBB-COMP-11877/news/Bristol-Myers-Squibb-Myers-Gets-CHMP-Positive-Opinion-for-Opdivo-Flat-Dosing-in-Melanoma-29247346/